Tag: liquid biopsy for cancer diagnostics industry share

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Liquid Biopsy For Cancer Diagnostics Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

The market size of liquid biopsy for cancer diagnostics has seen significant expansion in past years. From 2024 to 2025, the market size is expected to increase from $9.23 billion to $10.76 billion, with a compound annual growth rate (CAGR) of 16.6%. The cause for such development during the historic period can be credited to progress in genomic research, heightened awareness of the advantages of liquid biopsy, growth in cancer cases, a surge in demand for non-invasive cancer exams, and broadening of precision medicine initiatives._x000D_

_x000D_

In the coming years, the market size for liquid biopsy in cancer diagnosis is set to experience rapid expansion, reaching $19.24 billion in 2029 with a CAGR of 15.6%. This significant growth during the forecast period can be traced back to factors such as the integration of liquid biopsy into regular cancer diagnostic procedures, the adoption of this method for early cancer detection, the expansion of cancer screening programs, an increasing emphasis on personalized medicine within the field of oncology, as well as increased funding for research into liquid biopsy. Additionally, some notable trends during this forecast period include the emergence of multi-omics liquid biopsy approaches, the application of artificial intelligence in liquid biopsy analysis, the expansion of liquid biopsy applications beyond oncology, the development of blood-based biomarkers for cancer, and the customization of liquid biopsy assays for specific types of cancer._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp_x000D_

_x000D_

#Which Factors and External Forces Are Driving Demand in the Liquid Biopsy For Cancer Diagnostics Market?#_x000D_

The escalating rates of cancer are predicted to drive the expansion of the market for liquid biopsy in cancer diagnostics. Cancer encompasses a wide range of diseases that can occur in almost any organ or tissue when cells grow out of control, cross their normal limitations, and either spread to other organs or infiltrate adjacent body parts. This escalation in cancer augments the demand for diagnostic measures such as initial cancer recurrence or tumor detection, patient-specific risk assessment, and treatment monitoring. This permits liquid biopsy to illustrate the full magnitude of the disease as tumor cells or byproducts are discharged from all primary or metastatic tumor locations, offering comprehensive and real-time data on tumor cell development, therapeutic targets, and therapy resistance mechanisms. For instance, the National Cancer Institute, a government agency based in the US, reported in May 2024 that about 18.1 million individuals had survived cancer in the United States. This number is expected to grow to 22.5 million by 2032 and by 2040, the annual new cancer cases are anticipated to hit 29.9 million, with fatalities attributed to cancer predicted to climb to 15.3 million. As such, the escalating rates of cancer are fostering the expansion of the market for liquid biopsy in cancer diagnostics._x000D_

_x000D_

#Which Segments in the Liquid Biopsy For Cancer Diagnostics Offer the Most Growth?#_x000D_

The liquid biopsy for cancer diagnosticsmarket covered in this report is segmented – _x000D_

_x000D_

1) By Type: Product; Services_x000D_

2) By Sample: Blood; Urine; Saliva_x000D_

3) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers_x000D_

4) By End-User: Hospitals; Diagnostic Centers; Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits; Circulating Tumor DNA (ctDNA) Detection Kits; Exosome Isolation Kits; Sample Collection Devices _x000D_

2) By Services: Testing Services; Analytical Services; Bioinformatics Services _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Liquid Biopsy For Cancer Diagnostics Market?# Market?#_x000D_

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Cutting-Edge Market Trends Are Expected to Drive theLiquid Biopsy For Cancer Diagnostics Market’s Growth?#_x000D_

Product innovations are increasingly becoming a prominent trend in the liquid biopsy for cancer diagnostics market. Key players in the market are focusing their efforts on the development of innovative products to bolster their market standing. For instance, BostonGene, a biomedical software firm based in the U.S., in June 2023, introduced novel liquid biopsy solutions targeted at identifying clinically significant gene modifications. The expanded test repertoire aims to expedite the development of new tests, analytical tools, and workflows to deliver precision medicine to patients. Utilizing various AI-powered molecular and immunological profiling methods for tumor, microenvironment, and host immunity analysis, this innovation also aids in immunotherapy treatment. Furthermore, it provides information about a patient’s immune-related disorders and keeps track of disease progress and therapy response._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Liquid Biopsy For Cancer Diagnostics Market?#_x000D_

Liquid biopsy for cancer diagnostics is a less invasive method than traditional tissue biopsies, which include evaluating genetic material or biomarkers discovered in a patient’s blood or other bodily fluids to find and monitor the presence of cancer. It is commonly used for screening and identifying non-small cell lung cancer (NSCLC) and as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Liquid Biopsy For Cancer Diagnostics Market Growth in 2025?

In recent times, the market size for liquid biopsy in cancer diagnostics has seen swift growth. The projections show that it will increase from $9.23 billion in 2024 to $10.78 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.8%. The significant growth in the past can be related to the progress in genomic studies, escalating awareness about the perks of liquid biopsy, rising incidence of cancer, a surge in the requirement for non-invasive cancer diagnosis, and the broadening of precision medicine initiatives.

What Is the Forecast for the Liquid Biopsy For Cancer Diagnostics Market Size Through 2029?

The market for liquid biopsy in cancer diagnostics is predicted to witness rapid growth in the upcoming years, reaching $19.32 billion by 2029 with a compound annual growth rate (CAGR) of 15.7%. The acceleration during the forecast period can be credited to the incorporation of liquid biopsy in standard cancer diagnostics, the utilization of liquid biopsy in detecting cancer early, the broadening of cancer screening programs, an intensified emphasis on personalized medicine in oncology, and augmented financing for liquid biopsy research. Emerging trends during the forecast period comprise the development of multi-omics liquid biopsy methods, the inclusion of artificial intelligence in liquid biopsy analysis, the expansion of liquid biopsy applications beyond oncology, the creation of blood-based biomarkers for cancer, and the customization of liquid biopsy assays designed for specific types of cancer.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

What are the Key Market Players in Liquid Biopsy For Cancer Diagnostics Market and How They’re Evolving?

Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

What Are the Primary Growth Drivers in the Liquid Biopsy For Cancer Diagnostics Market?

The liquid biopsy for cancer diagnostics market is set to grow due to the increasing prevalence of cancer. Cancer, a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells to other organs or nearby tissues, necessitates diagnostic procedures such as early or recurring tumor detection, patient-specific risk evaluation, and treatment monitoring. The liquid biopsy method provides comprehensive and current data about tumor cell changes, therapeutic targets, and treatment resistance mechanisms by capturing the entirety of the disease, as it traces tumor cells or their byproducts released from all metastatic or primary tumor locations. As reported by the National Cancer Institute, a US-based government body, in May 2024, approximately 18.1 million people in the US had survived cancer. This number is anticipated to climb to 22.5 million by 2032. It is predicted that, by 2040, new cancer cases will increase to an annual figure of 29.9 million, while cancer-related deaths are expected to rise to 15.3 million. Thus, the escalating prevalence of cancer is fuelling the growth of the liquid biopsy for cancer diagnostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

What Are the Leading Segments in the Global Liquid Biopsy For Cancer Diagnostics Industry?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

What Are the Key Market Trends in the Liquid Biopsy For Cancer Diagnostics Industry?

Emergence of product innovations is a significant trend observed in the liquid biopsy for cancer diagnostics market. To solidify their presence in the market, key companies in this sector are focusing their efforts on developing innovative products. Take for example BostonGene, a biomedical software company based in the US. In June 2023, they rolled out new liquid biopsy solutions for the detection of clinically significant gene changes. This expanded testing portfolio is expected to accelerate the development of new assays, analytical instruments, and procedures for delivering precision medicine to patients. These solutions will leverage a variety of AI-powered molecular and immunological profiling techniques to assess tumors, microenvironments, and host immunity. Furthermore, it aids immunotherapy treatment, provides information on a patient’s immune-associated conditions, and tracks the progression of the disease and response to treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

What Is the Regional Outlook for the Liquid Biopsy For Cancer Diagnostics Market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205

This Report Delivers Insight On:

1. How big is the liquid biopsy for cancer diagnostics market, and how is it changing globally?

2. Who are the major companies in the liquid biopsy for cancer diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the liquid biopsy for cancer diagnostics market right now?

4. Which products or customer segments are growing the most in the liquid biopsy for cancer diagnostics market?

5. What factors are helping or slowing down the growth of the liquid biopsy for cancer diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the liquid biopsy for cancer diagnostics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has the Liquid Biopsy For Cancer Diagnostics Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the market size for liquid biopsy in cancer diagnostics has seen swift growth. The projections show that it will increase from $9.23 billion in 2024 to $10.78 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.8%. The significant growth in the past can be related to the progress in genomic studies, escalating awareness about the perks of liquid biopsy, rising incidence of cancer, a surge in the requirement for non-invasive cancer diagnosis, and the broadening of precision medicine initiatives.

The market for liquid biopsy in cancer diagnostics is predicted to witness rapid growth in the upcoming years, reaching $19.32 billion by 2029 with a compound annual growth rate (CAGR) of 15.7%. The acceleration during the forecast period can be credited to the incorporation of liquid biopsy in standard cancer diagnostics, the utilization of liquid biopsy in detecting cancer early, the broadening of cancer screening programs, an intensified emphasis on personalized medicine in oncology, and augmented financing for liquid biopsy research. Emerging trends during the forecast period comprise the development of multi-omics liquid biopsy methods, the inclusion of artificial intelligence in liquid biopsy analysis, the expansion of liquid biopsy applications beyond oncology, the creation of blood-based biomarkers for cancer, and the customization of liquid biopsy assays designed for specific types of cancer.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Factors and External Forces Are Driving Demand in the Liquid Biopsy For Cancer Diagnostics Market?

The liquid biopsy for cancer diagnostics market is set to grow due to the increasing prevalence of cancer. Cancer, a group of diseases characterized by the uncontrolled proliferation and spread of abnormal cells to other organs or nearby tissues, necessitates diagnostic procedures such as early or recurring tumor detection, patient-specific risk evaluation, and treatment monitoring. The liquid biopsy method provides comprehensive and current data about tumor cell changes, therapeutic targets, and treatment resistance mechanisms by capturing the entirety of the disease, as it traces tumor cells or their byproducts released from all metastatic or primary tumor locations. As reported by the National Cancer Institute, a US-based government body, in May 2024, approximately 18.1 million people in the US had survived cancer. This number is anticipated to climb to 22.5 million by 2032. It is predicted that, by 2040, new cancer cases will increase to an annual figure of 29.9 million, while cancer-related deaths are expected to rise to 15.3 million. Thus, the escalating prevalence of cancer is fuelling the growth of the liquid biopsy for cancer diagnostics market.

Which Segments in the Liquid Biopsy For Cancer Diagnostics Offer the Most Growth?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Liquid Biopsy For Cancer Diagnostics Market?# Market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theLiquid Biopsy For Cancer Diagnostics Market’s Growth?

Emergence of product innovations is a significant trend observed in the liquid biopsy for cancer diagnostics market. To solidify their presence in the market, key companies in this sector are focusing their efforts on developing innovative products. Take for example BostonGene, a biomedical software company based in the US. In June 2023, they rolled out new liquid biopsy solutions for the detection of clinically significant gene changes. This expanded testing portfolio is expected to accelerate the development of new assays, analytical instruments, and procedures for delivering precision medicine to patients. These solutions will leverage a variety of AI-powered molecular and immunological profiling techniques to assess tumors, microenvironments, and host immunity. Furthermore, it aids immunotherapy treatment, provides information on a patient’s immune-associated conditions, and tracks the progression of the disease and response to treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

What Are the Key Elements That Define the Liquid Biopsy For Cancer Diagnostics Market?

Liquid biopsy for cancer diagnostics is a less invasive method than traditional tissue biopsies, which include evaluating genetic material or biomarkers discovered in a patient’s blood or other bodily fluids to find and monitor the presence of cancer. It is commonly used for screening and identifying non-small cell lung cancer (NSCLC) and as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theLiquid Biopsy For Cancer Diagnostics Market?

The increasing occurrence of cancer is predicted to fuel the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer, a broad term for illnesses that can occur in virtually any organ or tissue in the body, happens when abnormal cells multiply without control, breach their usual limits, and either migrate to other organs or infiltrate nearby body parts. This proliferation boosts the necessity for diagnostic operations like early stage cancer or tumor recurrence detection, individual risk evaluation, and therapy monitoring. This allows liquid biopsy to show the full extent of the disease, as tumor or tumor byproducts are emitted from all metastatic or primary tumor locales, offering comprehensive and real-time data on tumor cell development, therapeutic objectives, and therapy resistance mechanisms. For context, in May 2024 the National Cancer Institute – a US government agency – reported approximately 18.1 million cancer survivors in the US alone. This number is predicted to climb to 22.5 million by 2032 and by 2040, the annual new cancer cases are believed to peak at 29.9 million, while cancer-related fatalities are forecasted to grow to 15.3 million. Hence, the increasing prevalence of cancer is contributing to the growth of the liquid biopsy for cancer diagnostics market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

#How Does the ProjectedLiquid Biopsy For Cancer Diagnostics Market Growth Compare Over the Forecast Period?

The market size for liquid biopsy in cancer diagnostics has experienced substantial growth in the past few years. A surge from $9.23 billion in 2024 to $10.78 billion in 2025 is expected, reflecting a compound annual growth rate (CAGR) of 16.8%. This growth during the historic period can be credited to progress in genomic research, increased understanding of the advantages of liquid biopsy, the escalating incidence of cancer, heightened demand for non-invasive cancer examination, and the broadening of precision medicine initiatives.

The market size for liquid biopsy in cancer diagnostics is projected to experience accelerated expansion in the upcoming years, swelling to reach $19.32 billion by 2029 with a 15.7% CAGR. This projected surge can be ascribed to factors such as, the incorporation of liquid biopsy into common cancer diagnostics, the increased use of liquid biopsy for early-stage cancer detection, the extension of cancer screening programs, a heightened emphasis on personalised medicine within oncology, and a surge in funding dedicated towards liquid biopsy research. Key trends predicted during the forecast period include the rise of multi-omics liquid biopsy methodologies, the incorporation of AI into liquid biopsy analysis, the application of liquid biopsy beyond oncology, the evolution of blood-based biomarkers for cancer, and the tailoring of liquid biopsy assays for particular types of cancer.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205

Which Cutting-Edge Market Trends Are Expected to Drive theLiquid Biopsy For Cancer Diagnostics Market’s Growth?

The rise of product innovations is becoming a prominent trend in the liquid biopsy for cancer diagnostics market, with key players focusing on developing innovative products to solidify their market position. An example of this is seen when BostonGene, an American biomedical software company, introduced new liquid biopsy solutions in June 2023 to detect clinically significant gene alterations. This expanded range of tests will expedite the development of novel assays, analysis tools, and processes that deliver precise medicine to patients. These methods encompass various AI-powered molecular and immunological profiling tools to study tumors, microenvironments, and host immunity. Furthermore, it supports immunotherapy treatment, provides insights into a patient’s immune-related issues, and keeps track of disease progression and treatment response.

What Are the Leading Market Players Impacting theLiquid Biopsy For Cancer Diagnostics Market’s Growth Trend?

Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

How Are the Key Segments of the Liquid Biopsy For Cancer Diagnostics Market Driving Opportunities and Innovations?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theLiquid Biopsy For Cancer Diagnostics Market?# Market Expansion?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal Liquid Biopsy For Cancer Diagnostics Maret 2025, By The Business Research Company:

Bioabsorbable Stents Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Cardiovascular Medical Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the liquid biopsy for cancer diagnostics market size evolved in recent years?

The market size of liquid biopsy for cancer detection has seen swift growth in the past few years. It is estimated to expand from $9.23 billion in 2024 to $10.78 billion in 2025, marking a compound annual growth rate (CAGR) of 16.8%. This significant growth in the historical period is due to the progress in genomic research, increased consciousness about the advantages of liquid biopsy, surging prevalence of cancer, escalating demand for non-invasive cancer diagnosis, and the growth of precision medicine initiatives.

What are the predictions for the liquid biopsy for cancer diagnostics market size in the coming years?

Anticipated to undergo swift expansion in the coming years, the liquid biopsy for cancer diagnostics market is predicted to reach a value of $19.32 billion in 2029, with a compound annual growth rate (CAGR) of 15.7%. Factors contributing to this growth forecast include the implementation of liquid biopsy in regular cancer diagnostics, the use of liquid biopsy for early cancer detection, growth of cancer screening programs, a heightened emphasis on personalized medicine in cancer care, and increased funding for research on liquid biopsy. Key trends that will shape the industry in the forecast period encompass the rise of multi-omics liquid biopsy methods, the incorporation of artificial intelligence in liquid biopsy examination, widening the use of liquid biopsy beyond cancer, the creation of blood-based biomarkers for cancer, and tailoring liquid biopsy tests for distinct types of cancer.

Get your liquid biopsy for cancer diagnostics market report here!

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

What key factors are fueling the growth of the liquid biopsy for cancer diagnostics market?

The escalating rate of cancer is anticipated to boost the expansion of the liquid biopsy for cancer diagnostics market. Cancer encompasses a broad range of diseases that can emerge anywhere in the body when abnormal cells multiply out of control, exceed their normal limits and either metastasize to other organs or infiltrate nearby body structures. Cancer amplifies the requirement for diagnostic routines such as early detection of cancer or tumor recurrence, risk analysis for each patient and monitoring of therapy, enabling liquid biopsy to reflect the complete disease landscape as tumor cells or tumor cell by-products are discharged from all metastatic or primary tumor locations, offering comprehensive and current data on tumor cell evolution, therapeutic objectives, and therapy resistance mechanisms. For example, the National Cancer Institute, a U.S. government agency, stated in May 2024 that about 18.1 million people in the United States survived cancer. This number is forecasted to shoot up to 22.5 million by the year 2032. By 2040, the recorded new cases of cancer per year is predicted to hit 29.9 million, where cancer relevant fatalities are speculated to surge to 15.3 million. Hence, the surging prevalence of cancer is fueling the progression of the liquid biopsy for cancer diagnostics market.

How is the global liquid biopsy for cancer diagnostics market divided into key segments?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Who are the key firms paving the way for growth in the liquid biopsy for cancer diagnostics market?

Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Which trends are expected to transform the liquid biopsy for cancer diagnostics market?

In the liquid biopsy for cancer diagnostics market, product innovation has rapidly become a key trend. To solidify their market presence, major firms in the field are focusing on the development of inventive products. For example, BostonGene, a biomedical software company from the US, introduced new liquid biopsy solutions in June 2023 to detect important gene changes clinically. The expansion of the test portfolio will speed up the development of new tests, analytical tools, and processes to give patients access to precision medicine. The approach amalgamates several artificial intelligence-powered techniques for molecular and immunological profiling to examine tumors, microenvironments, and host immunity. Furthermore, it aids in the delivery of immunotherapy treatment, supplies information on immune-system related diseases in patients, and keeps track of disease progression and response to therapy.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205

What regions are contributing significantly to the growth of the liquid biopsy for cancer diagnostics market?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Bioabsorbable Stents Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Cardiovascular Medical Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Are the Projected Expansion Rates of the Liquid Biopsy For Cancer Diagnostics Market for the Next Decade?

The liquid biopsy for cancer diagnostics market has witnessed substantial growth. It is forecasted to expand from $9.23 billion in 2024 to $10.78 billion in 2025, at a CAGR of 16.8%. This growth has been supported by advancements in genomic research, increasing awareness of liquid biopsy advantages, a rising incidence of cancer, growing demand for non-invasive cancer testing, and the expansion of precision medicine initiatives.

The liquid biopsy for cancer diagnostics market is projected to expand significantly, reaching $19.32 billion by 2029 at a CAGR of 15.7%. Growth in this sector is driven by increased adoption in routine cancer diagnostics, early detection initiatives, expansion of cancer screening programs, a stronger emphasis on personalized oncology, and rising research investments in liquid biopsy technologies. Key trends include the emergence of multi-omics liquid biopsy approaches, AI-powered biopsy analysis, expansion of applications beyond oncology, the development of blood-based cancer biomarkers, and tailored liquid biopsy assays for specific cancer types.

What Combination of Drivers Is Leading to Accelerated Growth in the liquid biopsy for cancer diagnostics Market?

The rising incidence of cancer is expected to drive the growth of the liquid biopsy for cancer diagnostics market. Cancer refers to a range of diseases characterized by abnormal cell growth. Liquid biopsies help detect early cancer or tumor recurrence, monitor therapy, and assess risks. The National Cancer Institute reported that there were 18.1 million cancer survivors in the U.S. in 2024, a figure expected to rise to 22.5 million by 2032. By 2040, the number of new cancer cases annually is projected to reach 29.9 million. Thus, the increasing incidence of cancer is contributing to the growth of the liquid biopsy market for cancer diagnostics.

Explore Comprehensive Insights Into The Global Liquid Biopsy For Cancer Diagnostics Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Companies Are Redefining the Future of the Liquid Biopsy For Cancer Diagnostics Market?

Major companies operating in the liquid biopsy for cancer diagnostics market include:

• F. Hoffman La Roche Ltd._x000D_

• Thermo Fisher Scientific Inc._x000D_

• Agilent Technologies Inc._x000D_

• Illumina Inc._x000D_

• The Menarini Group_x000D_

What Trends Are Poised to Drive the Future Success of the Liquid Biopsy For Cancer Diagnostics Market?

Product innovations are becoming a significant trend in the liquid biopsy for cancer diagnostics market. Leading companies are focusing on developing innovative products to strengthen their market presence. For example, in June 2023, BostonGene, a US-based biomedical software company, launched new liquid biopsy solutions to identify clinically relevant gene alterations. This expanded test portfolio will accelerate the creation of new assays, analytical tools, and pipelines, enabling precision medicine. The solution combines AI-driven molecular and immunological profiling to analyze tumors, microenvironments, and host immunity, supporting immunotherapy treatment and offering insights into immune-related disorders while monitoring disease progression and treatment response.

Secure Your Global Liquid Biopsy For Cancer Diagnostics Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Segments Play a Crucial Role in the Expansion of the Liquid Biopsy For Cancer Diagnostics Market?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

What Are the Leading Regions in the Liquid Biopsy For Cancer Diagnostics Market Expansion?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Liquid Biopsy For Cancer Diagnostics Market Classified and Defined in Market Analysis?

Liquid biopsy for cancer diagnostics is a less invasive method than traditional tissue biopsies, which include evaluating genetic material or biomarkers discovered in a patient’s blood or other bodily fluids to find and monitor the presence of cancer. It is commonly used for screening and identifying non-small cell lung cancer (NSCLC) and as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.

Browse Through More Similar Reports By The Business Research Company:

Bioabsorbable Stents Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Cardiovascular Medical Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Are the Projected Expansion Rates of the Liquid Biopsy For Cancer Diagnostics Market for the Next Decade?

The liquid biopsy for cancer diagnostics market has witnessed substantial growth. It is forecasted to expand from $9.23 billion in 2024 to $10.78 billion in 2025, at a CAGR of 16.8%. This growth has been supported by advancements in genomic research, increasing awareness of liquid biopsy advantages, a rising incidence of cancer, growing demand for non-invasive cancer testing, and the expansion of precision medicine initiatives.

The liquid biopsy for cancer diagnostics market is projected to expand significantly, reaching $19.32 billion by 2029 at a CAGR of 15.7%. Growth in this sector is driven by increased adoption in routine cancer diagnostics, early detection initiatives, expansion of cancer screening programs, a stronger emphasis on personalized oncology, and rising research investments in liquid biopsy technologies. Key trends include the emergence of multi-omics liquid biopsy approaches, AI-powered biopsy analysis, expansion of applications beyond oncology, the development of blood-based cancer biomarkers, and tailored liquid biopsy assays for specific cancer types.

What Combination of Drivers Is Leading to Accelerated Growth in the liquid biopsy for cancer diagnostics Market?

The rising incidence of cancer is expected to drive the growth of the liquid biopsy for cancer diagnostics market. Cancer refers to a range of diseases characterized by abnormal cell growth. Liquid biopsies help detect early cancer or tumor recurrence, monitor therapy, and assess risks. The National Cancer Institute reported that there were 18.1 million cancer survivors in the U.S. in 2024, a figure expected to rise to 22.5 million by 2032. By 2040, the number of new cancer cases annually is projected to reach 29.9 million. Thus, the increasing incidence of cancer is contributing to the growth of the liquid biopsy market for cancer diagnostics.

Explore Comprehensive Insights Into The Global Liquid Biopsy For Cancer Diagnostics Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Companies Are Redefining the Future of the Liquid Biopsy For Cancer Diagnostics Market?

Major companies operating in the liquid biopsy for cancer diagnostics market include:

• F. Hoffman La Roche Ltd._x000D_

• Thermo Fisher Scientific Inc._x000D_

• Agilent Technologies Inc._x000D_

• Illumina Inc._x000D_

• The Menarini Group_x000D_

What Trends Are Poised to Drive the Future Success of the Liquid Biopsy For Cancer Diagnostics Market?

Product innovations are becoming a significant trend in the liquid biopsy for cancer diagnostics market. Leading companies are focusing on developing innovative products to strengthen their market presence. For example, in June 2023, BostonGene, a US-based biomedical software company, launched new liquid biopsy solutions to identify clinically relevant gene alterations. This expanded test portfolio will accelerate the creation of new assays, analytical tools, and pipelines, enabling precision medicine. The solution combines AI-driven molecular and immunological profiling to analyze tumors, microenvironments, and host immunity, supporting immunotherapy treatment and offering insights into immune-related disorders while monitoring disease progression and treatment response.

Secure Your Global Liquid Biopsy For Cancer Diagnostics Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Segments Play a Crucial Role in the Expansion of the Liquid Biopsy For Cancer Diagnostics Market?

The liquid biopsy for cancer diagnostics market covered in this report is segmented –

1) By Type: Product, Services

2) By Sample: Blood, Urine, Saliva

3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices

2) By Services: Testing Services, Analytical Services, Bioinformatics Services

What Are the Leading Regions in the Liquid Biopsy For Cancer Diagnostics Market Expansion?

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Liquid Biopsy For Cancer Diagnostics Market Classified and Defined in Market Analysis?

Liquid biopsy for cancer diagnostics is a less invasive method than traditional tissue biopsies, which include evaluating genetic material or biomarkers discovered in a patient’s blood or other bodily fluids to find and monitor the presence of cancer. It is commonly used for screening and identifying non-small cell lung cancer (NSCLC) and as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.

Browse Through More Similar Reports By The Business Research Company:

Bioabsorbable Stents Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bioabsorbable-stents-global-market-report

Cardiovascular Medical Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

Blood Collection Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: